Literature DB >> 31875910

Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer.

Antonio Matrone1, Giovanni Ceccarini1, Marianna Beghini1, Federica Ferrari1, Carla Gambale1, Mariaida D'Aqui1, Paolo Piaggi2, Liborio Torregrossa3, Eleonora Molinaro1, Fulvio Basolo3, Paolo Vitti1, Ferruccio Santini1, Rossella Elisei1.   

Abstract

BACKGROUND: Obesity is a risk factor for several cancers, including differentiated thyroid cancer (DTC). Moreover, it has also been investigated as a potential risk factor for aggressiveness of DTC, but the data gathered so far are conflicting. The aim of our study was to evaluate the relationship between body mass index (BMI), aggressiveness of DTC at diagnosis, and clinical outcome.
METHODS: We evaluated 1058 consecutive DTC patients treated with total thyroidectomy and enrolled at the time of first radioactive iodine (131I) treatment. Patients were divided into 4 groups based on their BMI: underweight (< 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (≥ 30 kg/m2). Histological aggressiveness of DTC at the time of diagnosis and clinical outcome according to 2015 American Thyroid Association (ATA) guidelines were evaluated.
RESULTS: No differences in histological features, ATA risk of recurrence, activity of 131I administered and prevalence of 131I avid metastatic disease after first131I treatment, have been demonstrated among the groups. Furthermore, at the end of follow up (median = 5.7 years), no differences were evident in the number of further treatments performed as well as in the clinical response.
CONCLUSIONS: In our study group of Caucasian subjects, we could not demonstrate any association between BMI and aggressiveness of DTC, neither at the time of diagnosis nor during follow-up. These data indicate that postsurgical assessment and therapeutic attitude for treatment and follow-up of DTC should be based on the class of risk applied to the general population, with no concern for BMI. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  body mass index; differentiated thyroid cancer; histological features; obesity; radioiodine treatment

Year:  2020        PMID: 31875910     DOI: 10.1210/clinem/dgz312

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment.

Authors:  Sara Ahmadi; Theodora Pappa; Alex S Kang; Alexandra K Coleman; Iñigo Landa; Ellen Marqusee; Matthew Kim; Trevor E Angell; Erik K Alexander
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

2.  Association between metabolic syndrome and clinicopathological features of papillary thyroid cancer.

Authors:  Jun-Long Song; Ling-Rui Li; Xi-Zi Yu; Ling Zhan; Zhi-Liang Xu; Juan-Juan Li; Sheng-Rong Sun; Chuang Chen
Journal:  Endocrine       Date:  2021-11-26       Impact factor: 3.925

3.  Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy.

Authors:  Jingjia Cao; Xiaolu Zhu; Yaru Sun; Xiao Li; Canhua Yun; Wei Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

4.  Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis.

Authors:  Aliki Economides; Konstantinos Giannakou; Ioannis Mamais; Panayiotis A Economides; Panagiotis Papageorgis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-30       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.